Neuphoria Therapeutics (NEUP) Receivables - Other (2020 - 2026)

Neuphoria Therapeutics (NEUP) has reported Receivables - Other for 7 consecutive years, with $807945.0 the latest figure, recorded in Q1 2026.

• On a quarterly basis, Receivables - Other rose 27683.53% year-over-year to $807945.0 in Q1 2026; TTM through Mar 2026 was $807945.0, a 27683.53% increase from a year earlier, with the FY2025 full-year figure at $237.0, down 99.75% from the prior year.
• Receivables - Other was $807945.0 for Q1 2026 at Neuphoria Therapeutics, up from $488372.0 in the prior quarter.
• Over five years, Receivables - Other peaked at $4.8 million in Q2 2022 and troughed at $237.0 in Q2 2025.
• A 5-year average of $673260.8 and a median of $98389.5 in 2024 frame the typical range for Receivables - Other.
• Across the five-year window, Receivables - Other tumbled 99.75% in 2025 and surged 27683.53% in 2026, its largest moves.
• Over 5 years, Receivables - Other stood at $4.8 million in 2022, then sank by 91.29% to $419435.6 in 2023, then tumbled by 99.52% to $2021.0 in 2024, then soared by 24064.87% to $488372.0 in 2025, then soared by 65.44% to $807945.0 in 2026.
• The last three Receivables - Other figures came in at $807945.0 (Q1 2026), $488372.0 (Q4 2025), and $1758.0 (Q3 2025), per Business Quant data.